Literature DB >> 20649628

Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes.

C J Girman1, T D Kou, B Cai, C M Alexander, E A O'Neill, D E Williams-Herman, L Katz.   

Abstract

AIM: The aetiology of acute pancreatitis (AP) is complex, and many risk factors for AP are shared by patients with type 2 diabetes mellitus (T2DM). However, few have assessed risk factors for AP specifically in T2DM patients.
METHODS: Patients in the General Practice Research Database (2 984 755, 5.0% with T2DM) were used to estimate incidence of AP for T2DM relative to non-diabetes, adjusting for prior pancreatitis, gallbladder disease, obesity, smoking and alcohol use. Multivariate Cox regression analysis adjusting for risk factors and Charlson comorbidity index (CCI) was used to estimate hazard ratios (HR) with 95% confidence intervals (CI).
RESULTS: Between 2003 and 2007, 301 of 148 903 patients with T2DM and 2434 of almost 3 million patients without diabetes developed AP. Patients with T2DM had higher risk for AP compared with patients without diabetes (crude HR: 2.89, 95% CI: 2.56-3.27). Patients with T2DM had significantly higher rates of prior alcohol and tobacco exposure (44.2 and 61.9% vs. 34.1 and 35.9%, p < 0.001) and of comorbid conditions (14.7% with CCI > or =1 vs. 4.3%, p < 0.001). Histories of obesity, pancreatitis, gallbladder disease, smoking or alcohol use were significant predictors of AP. After adjusting for these factors, age, gender and comorbidities, the risk of developing AP remained elevated in patients with T2DM (adjusted HR: 1.49, 95% CI: 1.31-1.70).
CONCLUSION: After adjusting for risk factors, patients with T2DM had an elevated risk of AP compared with patients without diabetes. Physicians should be aware of the increased risk in patients with T2DM, particularly in those with prior pancreatitis.

Entities:  

Mesh:

Year:  2010        PMID: 20649628     DOI: 10.1111/j.1463-1326.2010.01231.x

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


  63 in total

Review 1.  Chronic Pancreatitis and the Development of Pancreatic Cancer.

Authors:  Hemanth K Kandikattu; Sathisha U Venkateshaiah; Anil Mishra
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2020       Impact factor: 2.895

2.  Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors: a population-based nested case-control study.

Authors:  Hsin-Chun Chou; Wen-Wen Chen; Fei-Yuan Hsiao
Journal:  Drug Saf       Date:  2014-07       Impact factor: 5.606

Review 3.  Issues in hypertriglyceridemic pancreatitis: an update.

Authors:  John Scherer; Vijay P Singh; C S Pitchumoni; Dhiraj Yadav
Journal:  J Clin Gastroenterol       Date:  2014-03       Impact factor: 3.062

Review 4.  [Upper abdominal pain: a frequent and multifaceted leading symptom in primary care internal medicine].

Authors:  G Fröhlich; H Fröhlich
Journal:  Internist (Berl)       Date:  2020-12-17       Impact factor: 0.743

Review 5.  Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies.

Authors:  Carlo B Giorda; Carlotta Sacerdote; Elisa Nada; Lisa Marafetti; Ileana Baldi; Roberto Gnavi
Journal:  Endocrine       Date:  2014-08-22       Impact factor: 3.633

6.  Diabetes aggravates acute pancreatitis possibly via activation of NLRP3 inflammasome in db/db mice.

Authors:  Lin Gao; Guo-Tao Lu; Ying-Ying Lu; Wei-Ming Xiao; Wen-Jian Mao; Zhi-Hui Tong; Na Yang; Bai-Qiang Li; Qi Yang; Yan-Bing Ding; Wei-Qin Li
Journal:  Am J Transl Res       Date:  2018-07-15       Impact factor: 4.060

7.  Chronic Pancreatitis in the 21st Century - Research Challenges and Opportunities: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Authors:  Aliye Uc; Dana K Andersen; Melena D Bellin; Jason I Bruce; Asbjørn M Drewes; John F Engelhardt; Christopher E Forsmark; Markus M Lerch; Mark E Lowe; Brent A Neuschwander-Tetri; Stephen J OʼKeefe; Tonya M Palermo; Pankaj Pasricha; Ashok K Saluja; Vikesh K Singh; Eva M Szigethy; David C Whitcomb; Dhiraj Yadav; Darwin L Conwell
Journal:  Pancreas       Date:  2016-11       Impact factor: 3.327

8.  GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: data from cardiovascular outcome trials.

Authors:  Chuqing Cao; Shuting Yang; Zhiguang Zhou
Journal:  Endocrine       Date:  2020-02-26       Impact factor: 3.633

9.  Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population.

Authors:  John A Romley; Dana P Goldman; Matthew Solomon; Daniel McFadden; Anne L Peters
Journal:  Diabetes Technol Ther       Date:  2012-07-30       Impact factor: 6.118

10.  Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis.

Authors:  Rajesh Garg; William Chen; Merri Pendergrass
Journal:  Diabetes Care       Date:  2010-08-03       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.